1887

Microbiology Society logo

Volume 128, Issue 10

Enhancement of Non-specific Resistance to Pseudomonas Pneumonia by a Synthetic Derivative of Muramoyl Dipeptide in Immunosuppressed Guinea Pigs Free

Abstract

A synthetic derivative of muramoyl dipeptide, 6--stearoyl--acetylmuramoyl--alanyl--iso-glutamine [L18-MDP(A)], showed a protective effect against bacteraemic and non-bacteraemic pneumonia caused by in immunosuppressed guinea pigs. In about half of the animals treated with the compound before infection, death from bacteraemic pneumonia produced by intratracheal inoculation of was delayed for 7 d, although all of the animals infected without prior treatment with the compound died within 4 d of infection. Multiplication of the organisms in the lung was also suppressed for at least 10 d by treatment with the compound when the animals inhaled an aerosol of . In contrast, in untreated animals the numbers of bacteria in the lung gradually increased from 10 to 10 c.f.u. g, and a few animals in which the organism increased to 10 c.f.u. g had died by 6 and 10 d after infection. In both healthy and immunosuppressed animals, the accumulation of polymorphonuclear leukocytes (PMNs) in a subcutaneous air-pouch injected with heat-killed organisms was augmented by subcutaneous treatment with L18-MDP(A) 1 d before bacterial injection. The phagocytic activity of peritoneal PMNs was also increased by treatment with this compound. The augmentation of protective mechanisms against pseudomonas pneumonia by L18-MDP(A) may be attributed at least partly to the increased chemotactic and phagocytic activity of PMNs.

  • Received:
  • Revised:
  • Published Online:
© Society for General Microbiology 1982
Loading

Article metrics loading...

/content/journal/micro/10.1099/00221287-128-10-2361
1982-10-01
2024-05-04
Loading full text...

Full text loading...

/deliver/fulltext/micro/128/10/mic-128-10-2361.html?itemId=/content/journal/micro/10.1099/00221287-128-10-2361&mimeType=html&fmt=ahah

References

  1. Azuma I., Sugimura K., Taniyama T., Yamawaki M., Yamamura Y., Kusumoto S., Okada S., Shibata T. 1976; Adjuvant activity of mycobacterial fractions: adjuvant activity of synthetic N-acetylmuramyl dipeptide and the related cornpounds. Infection and Immunity 14:18–27
     [Google Scholar]
  2. Bicker U., Hebold G., Ziegler A. E., Maus W. 1978; Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by 2-[-2-cyanazyridinyl-( 1 )-]-2-[-2-carbamoylazyridinyl-(l)]-propane BM 12531. Experimental Pathology, Jena 15:49–62
     [Google Scholar]
  3. Bodey G. P., Buckley M., Sathe Y. S., Freirich E. J. 1966; Quantitative relationships between circulating leukocyte and infection in patients with acute leukemia. Annals of Internal Medicine 64:328–340
     [Google Scholar]
  4. Buhles W. C., Shifrine M. 1977; Adjuvant protection against bacterial infection in granulocytopenic mice. Journal of Infectious Diseases 136:90–95
     [Google Scholar]
  5. Chedid L., Parant M., Parant F., Lefrancier P., Choay J., Lederer E. 1977; Enhancement of nonspecific immunity to Klebsiella pneumoniaeinfection by a synthetic immunoadjuvant (N-ace tylmuramyl-l-alanyl-d-isoglutamine) and several analogs. Proceedings of the National Academy of Sciences of the United States of America 74:2089–2093
     [Google Scholar]
  6. Dale D. C., Fauci A. S., Wolff S. M. 1973; The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with Wegener’s granulomatosis. Arthritis and Rheumatism 16:657–664
     [Google Scholar]
  7. Dale D. C., Fauci A. S., Wolff S. M. 1974; Alternate-day prednisone: leukocyte kinetics and susceptibility to infections. New England Journal of Medicine 28:1154–1158
     [Google Scholar]
  8. Dubos R. J., Schaedler R. W. 1957; Effects of cellular constituents of mycobacteria on the resistance to heterologous infections. I. Protective effect. Journal of Experimental Medicine 106:703–717
     [Google Scholar]
  9. Dukor P., Bianco C., Nussenzweig V. 1971; Bone marrow origin of complement-receptor lymphocytes. European Journal of Immunology 1:491–494
     [Google Scholar]
  10. Elin R. J., Wolff S. M., Chedid L. 1976; Nonspecific resistance to infection induced in mice by a water-soluble adjuvant derived from Mycobacterium smegmatis. Journal of Infectious Diseases 133:500–505
     [Google Scholar]
  11. Ellouz F., Adam A., Cirbaru R., Lederer E. 1974; Minimal structure requirement for adjuvant activity of bacterial peptidoglycan derivatives. Biochemical and Biophysical Research Communications 59:1317–1325
     [Google Scholar]
  12. Fryer H. C. 1966; Fisher’s test of least significant difference. In Concepts and Methods of Experimental Statistics p. 260 Boston: Allyn & Bacon;
     [Google Scholar]
  13. Gordee R. S., Simpson P. J. 1967; Relationships of X irradiation to the enhancement of Candida albicans infection. Journal of Bacteriology 94:6–12
     [Google Scholar]
  14. Gotze O., Muller-Eberhard H. J. 1971; The C3-activator system; an alternate pathway of complement activation. Journal of Experimental Medicine 134:90s–113s
     [Google Scholar]
  15. Howard L. G., Biozzi G., Halpern B. N., Stiffel C. C., Mouton D. 1959; The effect of Mycobacterium tuberculosis (BCG) infection on the resistance of mice to bacterial endotoxin and Salmonella enteritidis infection. British Journal of Experimental Pathology 40:281–291
     [Google Scholar]
  16. Ishii S. 1975; The Fisher’s test of direct probability. In Textbook of Statistics for Biological Experiments pp. 107–109 Tokyo: Baifukan;
     [Google Scholar]
  17. Ishikawa H., Niinobe S., Tsurufuji S. 1968; Studies of the mode of action of anti-inflammatory agents. I. Quantitative analysis of anti-inflammatory effect by carboxymethyl cellulose pouch method. Yakugaku Zasshi 88:1472–1477
     [Google Scholar]
  18. Kaplan H. S., Speck R. S., Jawetz E. 1952; Impairment of antimicrobial defenses following total body irradiation of mice. Journal of Laboratory and Clinical Medicine 40:682–691
     [Google Scholar]
  19. Landy M. 1956; Increase in resistance following administration of bacterial lipopolysaccharides. Annals of the New York Academy of Sciences 66:292–303
     [Google Scholar]
  20. Matsumoto K., Ogawa H., Kusama T., Nagase O., Sawaki N., Inage M., Kusumoto S., Shiba T., Azuma I. 1981; Stimulation of nonspecific resistance to infection induced by 6-O-acyl muramyl dipeptide analogs in mice. Infection and Immunity 32:748–758
     [Google Scholar]
  21. Parant M., Parant F., Chedid L., Le Minor L. 1975; Immunostimulants bactériens et protection de la souris infectée par Klebsiella pneumoniae résistante aux antibiotiques par mutation ou par transfert de plasmides. Annals de Immunologie 126:319–326
     [Google Scholar]
  22. Parant M., Parant F., Chedid L., Drapier J. C., Retitt J. F., Wiezerbin J., Lederer E. 1977; Enhancement of nonspecific immunity to bacterial infection by cord factor (6,6′-trehalose dimycolate). Journal of Infectious Diseases 135:771–777
     [Google Scholar]
  23. Parant M., Parant F., Chedid L. 1978; Enhancement of the neonate’s nonspecific immunity to Klebsiella infection by muramyl-dipeptide, a synthetic immunoadjuvant. Proceedings of the National Academy of Sciences of the United States of America 75:3395–3399
     [Google Scholar]
  24. Pennington J. E. 1977a; Quantitative effects of immunosuppression on bronchoalveolar cells. Journal of Infectious Diseases 136:127–131
     [Google Scholar]
  25. Pennington J. E. 1977b; Bronchoalveolar cell response to bacterial challenge in the immunosuppressed lung. American Review of Respiratory Disease 116:885–893
     [Google Scholar]
  26. Peters W. P., Holland J. F., Senn H., Rhomberg W., Banerjee T. 1972; Corticosteroid administration and localized leukocyte mobilization in man. New England Journal of Medicine 282:342–345
     [Google Scholar]
  27. Saslaw S., Carlisle H. N., Moheimant M. 1972; Effect of vincristine sulfate on Pseudomonas infections in monkeys. Infection and Immunity 6:149–155
     [Google Scholar]
  28. Sharbaugh R. J., Grogan J. B. 1969; Effect of cyclophosphamide on experimental Staphylococcus infection in the rat. Nature; London: 224809–810
     [Google Scholar]
  29. Sickles E. A., Greene W. H., Wiernik P. H. 1975; Clinical presentation of infection in granulocytopenic patients. Archives of Internal Medicine 135:715–719
     [Google Scholar]
  30. Tatsukawa K., Mitsuyama M., Takeya K., Nomoto K. 1979; Differing contribution of polymorphonuclear cells and macrophages to protection of mice against Listeria monocytogenes and Pseudomonas aeruginosa. Journal of General Microbiology 115:161–166
     [Google Scholar]
  31. Tripathy S. P., Mackaness G. B. 1969; The effect of cytotoxic agents on the primary immune response to Listeria monocytogenes. Journal of Experimental Medicine 130:1–16
     [Google Scholar]
  32. Ward P. A. 1966; The chemosuppression of chemotaxis. Journal of Experimental Medicine 124:209–229
     [Google Scholar]
  33. Young L. S., Armstrong D. 1972; Human immunity to Pseudomonas aeruginosa. I. In vitro interaction of bacteria, polymorphonuclear leukocyte, and serum factors. Journal of Infectious Diseases 126:257–276
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/00221287-128-10-2361
Loading
Enhancement of Non-specific Resistance to Pseudomonas Pneumonia by a Synthetic Derivative of Muramoyl Dipeptide in Immunosuppressed Guinea Pigs
Microbiology 128, 2361 (1982); https://doi.org/10.1099/00221287-128-10-2361
/content/journal/micro/10.1099/00221287-128-10-2361
/content/journal/micro/10.1099/00221287-128-10-2361
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error